US98422E1038
US98422E1038
Xeris Biopharma Holdings, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.91B EUR | 1.37B EUR | 1B EUR | 1.3B EUR |
Enterprise Value | 2.03B EUR | 1.54B EUR | 1.15B EUR | 1.45B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | 83.35x | 133.5x |
Forward P/E | 28.32x | -- | -- | -- |
Price to Sales | 5.7x | 4.1x | 3.18x | 5.63x |
Price to Book | -- | -- | 76.92x | 95.32x |
EV/Revenue | 6.04x | 4.6x | 3.65x | 6.27x |
EV/EBITDA | 41.53x | 28.21x | 21.48x | 35.32x |
Price to FCF (P/FCF) | 36.43x | 24.7x | 21.06x | 34.36x |
EV/FCF | 38.62x | 27.71x | 24.15x | 38.23x |
FCF Yield | 2.75% | 4.05% | 4.75% | 2.91% |